Samsung Biologics will accelerate its efforts to capture markets across Asia-Pacific (APAC), including Japan, by leveraging its 'End-to-End' contract development and manufacturing organization (CDMO) services, which allow for flexible responses to customer demand, as well as its capabilities in various new modalities (therapeutic approaches).
Samsung Biologics announced that it participated in 'BIO JAPAN 2026,' Asia's largest biopharmaceutical exhibition, and held a seminar on the first day of the event, the 7th, under the theme "Integrated CDMO Services and Optimization of Antibody-Drug Conjugate (ADC) Conjugation Processes Based on Computational Fluid Dynamics (CFD)."
At this seminar, Samsung Biologics presented a strategy to strengthen its leadership in the APAC market based on its solid business competitiveness. More than 200 industry professionals attended the session.
This year's BIO JAPAN is being held at the Pacifico Yokohama Convention Center from the 7th to the 9th of this month. Over 22,000 attendees are expected to visit the venue for this year's event. Samsung Biologics has participated for four consecutive years since 2023. The company plans to expand customer touchpoints and conduct order-winning activities with clients.
James Choi, Vice President of Sales Support at Samsung Biologics, who delivered a presentation at the seminar, stated, "With the active development of new modalities such as ADCs and peptides in Japan, demand for CDMO services is surging." He emphasized, "We will respond to rapidly changing customer needs not only by diversifying our service portfolio through the acquisition of capabilities in various modalities but also by providing End-to-End services that encompass contract research (CRO), contract development (CDO), and contract manufacturing (CMO)."
In addition to its core modality, antibody drugs, Samsung Biologics has a diverse business portfolio including mRNA (messenger ribonucleic acid) and ADCs. Furthermore, the company plans to fully launch its offensive in the peptide market by building multi-modality facilities through the construction of the Songdo 3rd Bio Campus and acquiring Polypeptide Group, a global peptide CDMO.
Vice President Choi also introduced the company's business achievements in Japan. Through its Tokyo sales office, which opened in 2025, Samsung Biologics is expanding local touchpoints with customers and conducting projects with numerous clients, including top 10 pharmaceutical companies in Japan.
Choi Yeon-jeong, a Professional at the New Modality Group of Samsung Biologics, who delivered the subsequent presentation, introduced high-quality manufacturing capabilities, such as process technologies that maintain consistent quality during scale-up of ADC production by utilizing advanced computational fluid dynamics (CFD) technology.
ADCs are a modality that attacks cancer cells identified via antibodies using a drug (payload). The mixing process, which ensures that the antibody and drug conjugate and separate as intended, is crucial in the high-quality pharmaceutical production process. In particular, when scaling up from small-scale production to large-scale commercial production, it is essential to maintain a uniform mixing environment.
Regarding this, Professional Choi explained, "We predicted the potential changes in the mixing environment using CFD technology, which analyzes fluid flow, heat transfer, and mass transfer through simulations." He added, "We confirmed that consistent ADC production quality can be maintained during scale-up."
Following BIO JAPAN, Samsung Biologics is scheduled to consecutively participate in domestic and international biopharmaceutical events, including 'CPHI Milan 2026' in Europe this month, 'World ADC San Diego' in the United States, and 'BIOPLUS-INTERPHARM Korea 2026' (BIX 2026) domestically.
in THEBIO
